Angiogenesis

Angiogenesis is a complex multifaceted process essential for cancer growth and progression. The underlying biology regulating angiogenesis is incredibly complicated, involving interaction between cancer cells and the tumor microenvironment. Angiogenic growth factor and receptor targets have been exploited to develop antiangiogenic therapies that have been successfully translated into clinical trials. Adoption of these agents into the clinical arena has improved survival in women with selected gynecologic cancers. The incorporation of bevacizumab, the most studied antiangiogenic, has received regulatory approval for the treatment of ovarian and cervical cancers. Further research has elucidated novel biomarkers and targets currently in preclinical and early clinical trial development. Translational research from pivotal trials has identified predictive biomarkers that can be explored in integral biomarker-directed trials. If successful, biomarkers to direct antiangiogenic therapy will identify women most likely to benefit from treatment and avoid unnecessary toxicity and cost.

Duke Scholars

Author Shara Reihani  

Author Angeles Alvarez Secord Obstetrics and Gynecology, Gynecologic Oncology